

Wendy A Cooper

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/199928/publications.pdf>

Version: 2024-02-01

95
papers

5,852
citations

145106

33
h-index

90395

73
g-index

96
all docs

96
docs citations

96
times ranked

8874
citing authors

#	ARTICLE	IF	CITATIONS
1	ROS1 rearrangements in lung adenocarcinomas are defined by diffuse strong immunohistochemical expression of ROS1. <i>Pathology</i> , 2022, 54, 399-403.	0.3	5
2	The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015. <i>Journal of Thoracic Oncology</i> , 2022, 17, 362-387.	0.5	429
3	The emerging role of the lung microbiome and its importance in non-small cell lung cancer diagnosis and treatment. <i>Lung Cancer</i> , 2022, 165, 124-132.	0.9	15
4	PD-L1 expression as a prognostic marker in patients treated with chemotherapy for metastatic non-small-cell lung cancer. <i>Future Oncology</i> , 2022, 18, 1793-1799.	1.1	6
5	Pathologist initiated reflex BRAF mutation testing in metastatic melanoma: experience at a specialist melanoma treatment centre. <i>Pathology</i> , 2022, , .	0.3	1
6	Fulminant Delta COVID-19 myocarditis: a case report of fatal primary cardiac dysfunction. <i>European Heart Journal - Case Reports</i> , 2022, 6, ytac142.	0.3	7
7	Abstract 5963: A framework for extrapolating evidence for molecularly targeted therapies from common to rare cancers - bridging the gap. <i>Cancer Research</i> , 2022, 82, 5963-5963.	0.4	0
8	Whole genome duplication in oral squamous cell carcinoma in patients younger than 50%years: implications for prognosis and adverse clinicopathological factors. <i>Genes Chromosomes and Cancer</i> , 2022, 61, 561-571.	1.5	2
9	Deep Learning-based Outcome Prediction in Progressive Fibrotic Lung Disease Using High-Resolution Computed Tomography. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 883-891.	2.5	29
10	Real-world programmed death-ligand 1 prevalence rates in non-small cell lung cancer: correlation with clinicopathological features and tumour mutation status. <i>Journal of Clinical Pathology</i> , 2021, 74, 123-128.	1.0	16
11	Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation. <i>Pathology</i> , 2021, 53, 141-156.	0.3	126
12	SP142 PD-L1 Scoring Shows High Interobserver and Intraobserver Agreement in Triple-negative Breast Carcinoma But Overall Low Percentage Agreement With Other PD-L1 Clones SP263 and 22C3. <i>American Journal of Surgical Pathology</i> , 2021, 45, 1108-1117.	2.1	26
13	The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 686-696.	0.5	13
14	Micronodular thymoma with lymphoid stroma: a clinicopathological study of five cases. <i>Pathology</i> , 2021, 53, 930-933.	0.3	2
15	Relationship between PD-L1 expression and outcome in EGFR-mutant lung cancer patients treated with EGFR tyrosine kinase inhibitors. <i>Lung Cancer</i> , 2021, 155, 28-33.	0.9	18
16	Primary membranous glomerulonephritis with negative serum PLA2R in haemophilia A successfully managed with rituximab - case report and review of the literature. <i>BMC Nephrology</i> , 2021, 22, 268.	0.8	2
17	Disseminated intravascular coagulation complicating diagnosis of ROS1 -mutant non-small cell lung cancer: A case report and literature review. <i>Thoracic Cancer</i> , 2021, 12, 2400-2403.	0.8	6
18	Predicting Response to Programmed Cell Death Protein-1 or Programmed Death-Ligand 1 Blockade in NSCLC - Is Multiplex Immunohistochemistry or Immunofluorescence the Answer?. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1247-1249.	0.5	2

#	ARTICLE	IF	CITATIONS
19	Efficacy of immunotherapy in <i>KRAS</i> -mutant non-small-cell lung cancer with comutations. <i>Immunotherapy</i> , 2021, 13, 941-952.	1.0	14
20	Updates in the molecular pathology of non-small cell lung cancer. <i>Seminars in Diagnostic Pathology</i> , 2021, 38, 54-61.	1.0	10
21	Molecular testing in stage III non-small cell lung cancer: Approaches and challenges. <i>Lung Cancer</i> , 2021, 162, 42-53.	0.9	22
22	Diagnostic accuracy of transbronchial lung cryobiopsy for interstitial lung disease diagnosis (COLDICE): a prospective, comparative study. <i>Lancet Respiratory Medicine</i> , 2020, 8, 171-181.	5.2	253
23	PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee. <i>Journal of Thoracic Oncology</i> , 2020, 15, 499-519.	0.5	203
24	Adequate tumour cellularity is essential for accurate PD-L1 immunohistochemistry assessment on cytology cell block specimens. <i>Cytopathology</i> , 2020, 31, 90-95.	0.4	20
25	Targeting CD83 in mantle cell lymphoma with anti-human CD83 antibody. <i>Clinical and Translational Immunology</i> , 2020, 9, e1156.	1.7	3
26	Lung Cancer in Australia. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1809-1814.	0.5	13
27	Methodologies of COLDICE and Cryo-PID studies: details make the difference. <i>Annals of Translational Medicine</i> , 2020, 8, 781-781.	0.7	1
28	The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1409-1424.	0.5	182
29	<i>ALK</i> -Rearranged Non-Small Cell Lung Cancer in 2020: Real-World Triumphs in an Era of Multigeneration <i>ALK</i> -Inhibitor Sequencing Informed by Drug Resistance Profiling. <i>Oncologist</i> , 2020, 25, 641-649.	1.9	8
30	A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1599-1610.	0.5	234
31	Histopathologic Assessment of Suspected Idiopathic Pulmonary Fibrosis: Where We Are and Where We Need to Go. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 1477-1489.	1.2	14
32	IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy. <i>Journal of Thoracic Oncology</i> , 2020, 15, 709-740.	0.5	205
33	Blood monocyte counts as a potential prognostic marker for idiopathic pulmonary fibrosis: analysis from the Australian IPF registry. <i>European Respiratory Journal</i> , 2020, 55, 1901855.	3.1	23
34	Retrospective Evaluation of the Use of Pembrolizumab in Malignant Mesothelioma in a Real-World Australian Population. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100075.	0.6	8
35	FISH analysis of selected soft tissue tumors: Diagnostic experience in a tertiary center. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019, 15, 38-47.	0.7	11
36	Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer. <i>Future Oncology</i> , 2019, 15, 2371-2383.	1.1	4

#	ARTICLE	IF	CITATIONS
37	Australian consensus statement for best practice ROS1 testing in advanced non-small cell lung cancer. <i>Pathology</i> , 2019, 51, 673-680.	0.3	8
38	<i>TERT</i> gene: its function and dysregulation in cancer. <i>Journal of Clinical Pathology</i> , 2019, 72, 281-284.	1.0	63
39	Gastroesophageal reflux and antacid therapy in IPF: analysis from the Australia IPF Registry. <i>BMC Pulmonary Medicine</i> , 2019, 19, 84.	0.8	26
40	Malignant gastrointestinal neuroectodermal tumour (GNET): neural mesenchymal tumours of the gastrointestinal tract with striking histology and EWSR1 gene rearrangement. <i>Pathology</i> , 2019, 51, 324-327.	0.3	2
41	High BIN1 expression has a favorable prognosis in malignant pleural mesothelioma and is associated with tumor infiltrating lymphocytes. <i>Lung Cancer</i> , 2019, 130, 35-41.	0.9	17
42	Clinical Utility of In Situ Hybridization Assays in Head and Neck Neoplasms. <i>Head and Neck Pathology</i> , 2019, 13, 397-414.	1.3	5
43	Implications of the diagnostic criteria of idiopathic pulmonary fibrosis in clinical practice: Analysis from the Australian Idiopathic Pulmonary Fibrosis Registry. <i>Respirology</i> , 2019, 24, 361-368.	1.3	24
44	Cryobiopsy versus open lung biopsy in the diagnosis of interstitial lung disease (COLDICE): protocol of a multicentre study. <i>BMJ Open Respiratory Research</i> , 2019, 6, e000443.	1.2	17
45	Pigmented Paget's disease of the nipple mistaken for melanoma in situ : a diagnostic pitfall for the unwary. <i>Pathology</i> , 2018, 50, 364-367.	0.3	3
46	Pattern of care and survival of anaplastic lymphoma kinase rearranged non-small cell lung cancer (<i>ALK</i> + NSCLC) in an Australian Metropolitan Tertiary Referral Centre: A retrospective cohort analysis. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, e275-e282.	0.7	6
47	CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphoma. <i>Haematologica</i> , 2018, 103, 655-665.	1.7	24
48	Comparison of Four PD-L1 Immunohistochemical Assays in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 367-376.	0.5	127
49	Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma. <i>JAMA Oncology</i> , 2018, 4, 210.	3.4	437
50	Response to Editorial: The PD-L1 Immunohistochemistry Biomarker: Two Steps Forward, One Step Back?. <i>Journal of Thoracic Oncology</i> , 2018, 13, e185-e186.	0.5	1
51	Targeted Molecular Treatments in Non-Small Cell Lung Cancer: A Clinical Guide for Oncologists. <i>Journal of Clinical Medicine</i> , 2018, 7, 192.	1.0	27
52	Immunotherapy in Non-Small Cell Lung Cancer: Shifting Prognostic Paradigms. <i>Journal of Clinical Medicine</i> , 2018, 7, 151.	1.0	11
53	An Update on Predictive Biomarkers for Treatment Selection in Non-Small Cell Lung Cancer. <i>Journal of Clinical Medicine</i> , 2018, 7, 153.	1.0	47
54	Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry. <i>BMC Pulmonary Medicine</i> , 2018, 18, 19.	0.8	58

#	ARTICLE	IF	CITATIONS
55	Understanding Immune Tolerance of Cancer: Reâ€Purposing Insights from Fetal Allografts and Microbes. <i>BioEssays</i> , 2018, 40, e1800050.	1.2	8
56	Biomarkers for ALK and ROS1 in Lung Cancer: Immunohistochemistry and Fluorescent In Situ Hybridization. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 922-928.	1.2	20
57	Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry. <i>European Respiratory Journal</i> , 2017, 49, 1601592.	3.1	174
58	Healthâ€related quality of life in idiopathic pulmonary fibrosis: Data from the <sc>A</sc>ustralian <sc>IPF R</sc>egistry. <i>Respirology</i> , 2017, 22, 950-956.	1.3	85
59	Intra- and Interobserver Reproducibility Assessment of PD-L1 Biomarker in Nonâ€Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 4569-4577.	3.2	96
60	The Use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and Its Differential Diagnosis. An International Reproducibility Study in a Demanding Set of Cases. <i>Journal of Thoracic Oncology</i> , 2017, 12, 334-346.	0.5	113
61	Determinants and outcomes of prolonged anxiety and depression in idiopathic pulmonary fibrosis. <i>European Respiratory Journal</i> , 2017, 50, 1700168.	3.1	32
62	Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. <i>Lancet Oncology</i> , The, 2017, 18, 1386-1396.	5.1	508
63	Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant PleuralâMesothelioma. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1421-1433.	0.5	121
64	Screening for <i><sc>ROS</sc>1</i> gene rearrangements in nonâ€smallâ€cell lung cancers using immunohistochemistry with <sc>FISH</sc> confirmation is an effective method to identify this rare target. <i>Histopathology</i> , 2017, 70, 402-411.	1.6	52
65	EGFRâ€Co-Mutated Advanced NSCLC and Response toâEGFR Tyrosine Kinase Inhibitors. <i>Journal of Thoracic Oncology</i> , 2017, 12, 585-590.	0.5	52
66	Spindle cell variant of diffuse large B cell lymphoma occurring in the breast. <i>Pathology</i> , 2017, 49, 784-786.	0.3	2
67	The molecular profile of metastatic melanoma in Australia. <i>Pathology</i> , 2016, 48, 188-193.	0.3	26
68	Atypical Ewing sarcoma breakpoint region 1 fluorescence <i>inâ€situ</i> hybridization signal patterns in bone and soft tissue tumours: diagnostic experience with 135 cases. <i>Histopathology</i> , 2016, 69, 1000-1011.	1.6	12
69	Clinical impact of the interstitial lung disease multidisciplinary service. <i>Respirology</i> , 2016, 21, 1438-1444.	1.3	84
70	<i>BRAF</i>^{V600E} and <i>NRAS</i>^{Q61L/Q61R} mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting. <i>Histopathology</i> , 2016, 69, 680-686.	1.6	28
71	A proteomics-based approach identifies secreted protein acidic and rich in cysteine as a prognostic biomarker in malignant pleural mesothelioma. <i>British Journal of Cancer</i> , 2016, 114, 524-531.	2.9	20
72	The Role of Tumor-Infiltrating Lymphocytes in Development, Progression, and Prognosis of Nonâ€Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 789-800.	0.5	401

#	ARTICLE	IF	CITATIONS
73	Alterations of MET Gene Copy Number and Protein Expression in Primary Non-Small-Cell Lung Cancer and Corresponding Nodal Metastases. <i>Clinical Lung Cancer</i> , 2016, 17, 30-38.e1.	1.1	22
74	Episodic fevers and vasodilatory shock mimicking urosepsis in a patient with HIV-associated multicentric Castleman's Disease: a case report. <i>BMC Infectious Diseases</i> , 2015, 16, 53.	1.3	2
75	PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. <i>Lung Cancer</i> , 2015, 89, 181-188.	0.9	253
76	Equivocal ALK fluorescence in-situ hybridization (FISH) cases may benefit from ancillary ALK FISH probe testing. <i>Histopathology</i> , 2015, 67, 654-663.	1.6	15
77	HER2 insertion YVMA mutant lung cancer: Long natural history and response to afatinib. <i>Lung Cancer</i> , 2015, 90, 617-619.	0.9	34
78	miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma. <i>Oncotarget</i> , 2015, 6, 23480-23495.	0.8	76
79	BRAF mutations in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2015, 4, 142-8.	1.3	41
80	The suitability of small biopsy and cytology specimens for EGFR and other mutation testing in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2015, 4, 119-25.	1.3	35
81	Preface-molecular genetics of lung cancer. <i>Translational Lung Cancer Research</i> , 2015, 4, 109.	1.3	3
82	Response to Mahe. <i>Modern Pathology</i> , 2014, 27, 1424-1425.	2.9	1
83	National Working Group Meeting on ALK diagnostics in lung cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2014, 10, 11-17.	0.7	11
84	Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. <i>Modern Pathology</i> , 2013, 26, 1545-1553.	2.9	138
85	Fibroblast growth factor receptor 1 (FGFR1) copy number is an independent prognostic factor in non-small cell lung cancer. <i>Lung Cancer</i> , 2013, 81, 462-467.	0.9	66
86	Patterns of DNA Mutations and ALK Rearrangement in Resected Node Negative Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2013, 8, 408-414.	0.5	38
87	Molecular biology of lung cancer. <i>Journal of Thoracic Disease</i> , 2013, 5 Suppl 5, S479-90.	0.6	173
88	Loss of Special AT-Rich Binding Protein 1 Expression is a Marker of Poor Survival in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1179-1189.	0.5	76
89	What's new in non-small cell lung cancer for pathologists the importance of accurate subtyping, EGFR mutations and ALK rearrangements. <i>Pathology</i> , 2011, 43, 103-115.	0.3	54
90	Expression and prognostic significance of cyclin B1 and cyclin A in non-small cell lung cancer. <i>Histopathology</i> , 2009, 55, 28-36.	1.6	58

#	ARTICLE	IF	CITATIONS
91	Role and prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand death receptor DR5 in nonsmall-cell lung cancer and precursor lesions. <i>Cancer</i> , 2008, 113, 135-142.	2.0	33
92	An unusual pleural spindle cell tumour Part 1. <i>Pathology</i> , 2002, 34, 370-374.	0.3	3
93	¹ H NMR visible lipids are induced by phosphonium salts and 5-fluorouracil in human breast cancer cells. <i>Magnetic Resonance in Medicine</i> , 2001, 45, 1001-1010.	1.9	33
94	Induction of magnetic resonance-visible lipid in a transformed human breast cell line by tetraphenylphosphonium chloride. , 1997, 73, 570-579.		16
95	Induction of magnetic resonance-visible lipid in a transformed human breast cell line by tetraphenylphosphonium chloride. <i>International Journal of Cancer</i> , 1997, 73, 570-579.	2.3	1